972
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Diagnostic value of BinaxNOW antigen card for Severe Acute Respiratory Syndrome Coronavirus 2

, , , , , , , , & show all
Article: 2180221 | Received 17 Apr 2022, Accepted 26 Jul 2022, Published online: 25 Jul 2023

References

  • Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–140.
  • Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41(12):1100–1115.
  • Atzrodt CL, Maknojia I, McCarthy RDP, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020;287(17):3633–3650.
  • Trougakos IP, Stamatelopoulos K, Terpos E, et al. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J Biomed Sci. 2021;28(1):9.
  • World Health Organization. WHO coronavirus (COVID-19) dashboard [internet]. 2021 [updated 2021 Sept 3rd; cited 2021 Sept 3rd]. Available from: https://covid19.who.int/.
  • Chourasia R, Padhi S, Phukon LC, et al. Peptide candidates for the development of therapeutics and vaccines against β-coronavirus infection. Bioengineered. 2022;13(4):9435–9454.
  • Chu DT, Vu Ngoc SM, Vu Thi H, et al. COVID-19 in Southeast Asia: current status and perspectives. Bioengineered. 2022;13(2):3797–3809.
  • Yuce M, Filiztekin E, Ozkaya KG. COVID-19 diagnosis -A review of current methods. Biosens Bioelectron. 2021;172(112752):112752.
  • Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites - Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):100–105.
  • Islam KU, Iqbal J. An update on molecular diagnostics for COVID-19. Front Cell Infect Microbiol. 2020;10:560616.
  • Taleghani N, Taghipour F. Diagnosis of COVID-19 for controlling the pandemic: a review of the state-of-the-art. Biosens Bioelectron. 2021;174(112830):112830.
  • Bui LM, Thi Thu Phung H, Ho Thi TT, et al. Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review. Bioengineered. 2021;12(1):8594–8613.
  • Abbott. BinaxNOW: what you need to know [Internet]. 2022 [updated 11st Mar 2022; cited 2022; cited 29th May 2022 Mar 2022; cited 29th May 11st Mar 2022; cited 29th]. Available from: https://www.abbott.com/corpnewsroom/diagnostics-testing/BinaxNOW-what-you-need-to-know.html.
  • Peacock WF, Soto-Ruiz KM, House SL, et al. Utility of COVID-19 antigen testing in the emergency department. J Am Coll Emerg Physicians Open. 2022;3(1):e12605.
  • Shah MM, Salvatore PP, Ford L, et al. Performance of repeat BinaxNOW severe acute respiratory syndrome coronavirus 2 antigen testing in a community setting, Wisconsin, November 2020-December 2020. Clin Infect Dis. 2021;73(Suppl 1):S54–S57.
  • Toropov N, Osborne E, Joshi LT, et al. sars-cov-2 tests: bridging the gap between laboratory sensors and clinical applications. ACS Sens. 2021;6(8):2815–2837.
  • The US Food and Drug Administration. BinaxNOW COVID-19 Ag Card—Letter of Authorization 2020 [updated 26th Aug 2020; cited 2020; cited 4th May 2021 Aug 2020; cited 4th May 26th Aug 2020; cited 4th]. Available from: https://www.fda.gov/media/141567/download.
  • Sood N, Shetgiri R, Rodriguez A, et al. Evaluation of the abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection in children: implications for screening in a school setting. PLoS One. 2021;16(4):e0249710.
  • Perchetti GA, Huang ML, Mills MG, et al. Analytical sensitivity of the Abbott BinaxNOW COVID-19 Ag Card. J Clin Microbiol. 2021;59:3.
  • Pilarowski G, Lebel P, Sunshine S, et al. Performance characteristics of a rapid severe acute respiratory syndrome coronavirus 2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021;223(7):1139–1144.
  • U.S. Department of Health & Human Services. biden-harris administration requires insurance companies and group health plans to cover the cost of at-home covid-19 tests, increasing access to free tests [internet]. 2022 [updated 10th Jan 2022; cited 2022; cited 29th May 2022 Jan 2022; cited 29th May 10th Jan 2022; cited 29th]. Available from: https://www.hhs.gov/about/news/2022/01/10/biden-harris-administration-requires-insurance-companies-group-health-plans-to-cover-cost-at-home-covid-19-tests-increasing-access-free-tests.html.
  • McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–396.
  • Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2(9). DOI:10.1186/1471-2288-2-9.
  • Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536.
  • Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006;6(31).
  • Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: q statistic or I2 index? Psychol Methods. 2006;11(2):193–206.
  • Leeflang MM. Systematic reviews and meta-analyses of diagnostic test accuracy. Clin Microbiol Infect. 2014;20(2):105–113.
  • McKay SL, Tobolowsky FA, Moritz ED, et al. Performance evaluation of serial SARS-CoV-2 rapid antigen testing during a nursing home outbreak. Ann Intern Med. 2021;174(7):945–951.
  • James AE, Gulley T, Kothari A, et al. Performance of the BinaxNOW coronavirus disease 2019 (COVID-19) Antigen Card test relative to the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assay among symptomatic and asymptomatic healthcare employees. Infect Control Hosp Epidemiol. 2022 Jan;431:99–101. DOI:10.1017/ice.2021.20. Epub 2021 Jan 25. PMID: 33487197; PMCID: PMC7870908.
  • Pollock NR, Jacobs JR, Tran K, et al. Performance and Implementation Evaluation of the Abbott BinaxNOW Rapid Antigen Test in a High-Throughput Drive-Through Community Testing Site in Massachusetts. J Clin Microbiol. 2021;59(5). DOI:10.1128/JCM.00083-21.
  • Pilarowski G, Marquez C, Rubio L, et al. Field performance and public health response using the BinaxNOWTM rapid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen detection assay during community-based testing. Clinl Infect Dis. 2021 Nov 2;73(9):e3098–e3101. DOI:10.1093/cid/ciaa1890. PMID: 33367619; PMCID: PMC7799223.
  • Mistry DA, Wang JY, Moeser ME, et al. A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2. BMC Infect Dis. 2021;21(1):828.
  • Okoye NC, Barker AP, Curtis K, et al. Performance characteristics of BinaxNOW COVID-19 antigen card for screening asymptomatic individuals in a university setting. J Clin Microbiol. 2021;59(4). DOI:10.1128/JCM.03282-20.
  • Esbin MN, Whitney ON, Chong S, et al. Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection. RNA. 2020;26(7):771–783.
  • Yang F, Liu L, Neuenschwander PF, et al. Phage display-derived peptide for the specific binding of SARS-CoV-2. ACS omega. 2022;7(4):3203–3211.
  • Huijskens EG, Biesmans RC, Buiting AG, et al. Diagnostic value of respiratory virus detection in symptomatic children using real-time PCR. Virol J. 2012;9(276). DOI:10.1186/1743-422X-9-276
  • Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337–350.
  • Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021;3(3):Cd013705.
  • World Health Organization. Target product profiles for priority diagnostics to support response to the COVID-19 pandemic 2020 [updated 28th Sept 2020; cited 2020; cited 4th May 2021 Sept 2020; cited 4th May 28th Sept 2020; cited 4th]. Available from: https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1.
  • The US Food and Drug Administration. BinaxNOW COVID-19 Ag card home test [Internet]. 2021 [updated 29th Mar 2021; cited 2021; cited 4th May 2021 Mar 2021; cited 4th May 29th Mar 2021; cited 4th]. Available from: https://www.fda.gov/media/144576/download.
  • Larremore DB, Wilder B, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. 2021;7(1). DOI:10.1126/sciadv.abd5393.
  • Schrom J, Marquez C, Pilarowski G, et al. Comparison of SARS-CoV-2 reverse transcriptase polymerase chain reaction and BinaxNOW rapid antigen tests at a community site during an omicron surge: a cross-sectional study. Ann Intern Med. 2022;175(5):682–690.
  • Lindner AK, Nikolai O, Kausch F, et al. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. Eur Respir J. 2021 Apr 15;57(4):2003961. DOI:10.1183/13993003.03961-2020. PMID: 33303544; PMCID: PMC7736752.